Author + information
- Received April 6, 2011
- Revision received April 18, 2011
- Accepted May 3, 2011
- Published online July 1, 2011.
- Ryan D. Madder, MD⁎ (, )
- Robert D. Safian, MD,
- Michael Gallagher, MD,
- Shaun R. Senter, MD and
- George S. Hanzel, MD
- ↵⁎Reprint requests and correspondence:
Dr. Ryan D. Madder, Department of Cardiovascular Medicine, William Beaumont Hospital, 3601 West Thirteen Mile Road, Royal Oak, Michigan 48073
Recent publication of the PARTNER (Placement of AoRTic TraNscathetER Valve) and EVEREST (Endovascular Valve Edge-to-Edge REpair Study) trials support the safety and efficacy of transcatheter aortic valve implantation and percutaneous mitral valve repair (1–3). The present report is that of an 82-year-old man with severe aortic stenosis presenting in October 2005 with dyspnea. He was deemed a poor candidate for surgical aortic valve replacement, due to remote coronary bypass surgery and open repair of an infarct-related ventricular septal defect. In December 2005, he underwent successful transcatheter aortic valve implantation with an Edwards SAPIEN transcatheter heart valve (Edwards Lifesciences, Irvine, California).
Five years later, he developed progressive heart failure attributable to severe mitral regurgitation from a restricted posterior leaflet. In September 2010, he underwent percutaneous mitral valve repair with an Evalve MitraClip (Evalve, San Francisco, California). Fluoroscopy reveals both percutaneously deployed aortic and mitral valve devices (Fig. 1). At follow-up 7 months later, the patient reports walking 1 mile for exercise several times/week.
Dr. Safian received research support from Abbott Vascular and Edwards Lifesciences. Dr. Hanzel is a proctor for Gore and AGA. All other authors have reported that they have no relationships to disclose.
- Received April 6, 2011.
- Revision received April 18, 2011.
- Accepted May 3, 2011.
- American College of Cardiology Foundation
- Feldman T.,
- Kar S.,
- Rinaldi M.,
- et al.